Ensysce Biosciences (ENSCW) Common Equity (2017 - 2025)

Ensysce Biosciences (ENSCW) has 9 years of Common Equity data on file, last reported at $3.2 million in Q4 2025.

• Common Equity for Q4 2025 came in at $3.2 million, down 4.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.2 million (down 4.92% YoY), and the FY2025 annual result was $3.2 million, down 4.92% from the prior year.
• Common Equity improved to $3.2 million in Q4 2025 per ENSCW's latest filing, from $1.2 million in the prior quarter.
• Over five years, Common Equity peaked at $6.6 million in Q3 2024 and troughed at -$8.2 million in Q4 2021.
• A 5-year average of $419355.2 and a median of $1.2 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity plunged 1566.79% in 2022, then soared 2344.15% in 2024.
• A 5-year view of Common Equity shows it stood at -$8.2 million in 2021, then jumped by 50.61% to -$4.0 million in 2022, then soared by 83.84% to -$651267.0 in 2023, then soared by 618.98% to $3.4 million in 2024, then slipped by 4.92% to $3.2 million in 2025.
• Business Quant data shows ENSCW's Common Equity at $3.2 million in Q4 2025, $1.2 million in Q3 2025, and $3.1 million in Q2 2025.